Balyasny Asset Management L.P.

Position in ATYR — aTYR PHARMA INC

CIK 1218710 Chicago, IL

Back to ATYR Full portfolio

Position in ATYR

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$8,057

+$8,057 QoQ

Shares Held

10,330

Ownership

0.011%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#78

of 109 holders

Holding Since

Dec 2024

4 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in ATYR Over Time

Shares Held

Position Value (USD)

Derivatives in ATYR

reported options exposure · as of Sep 30, 2025

CallValue

$72,100

CallShares

100,000

PutValue

$288,400

PutShares

400,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

Balyasny Asset Management L.P. holds $2,162,763,632 across 176 Biotechnology names. ATYR ranks #174 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	TERN	Terns Pharmaceuticals, Inc.	2,779,445	$146,532,340
2	ERAS	Erasca, Inc.	5,143,985	$83,229,677
3	TNGX	Tango Therapeutics, Inc.	3,826,659	$80,053,706
4	APLS	Apellis Pharmaceuticals, Inc.	1,917,501	$77,141,065
5	BMRN	Biomarin Pharmaceutical Inc	1,362,752	$76,981,860
6	CYTK	Cytokinetics Inc	992,545	$65,418,640
7	DAWN	Day One Biopharmaceuticals, Inc.	2,625,235	$56,285,038
8	FOLD	AMICUS THERAPEUTICS, INC.	3,827,513	$55,345,837

All Filings in ATYR

Export CSV

5 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$8,057	10,330	-97.4%	Shares	Sole	2026-05-15
2025-09-30	$288,400	400,000	+300.0%	Put	Sole	2025-11-14
2025-09-30	$72,100	100,000	-56.0%	Call	Sole	2025-11-14
2025-03-31	$685,968	227,142	+412.6%	Shares	Sole	2025-05-15
2024-12-31	$160,402	44,310	—	Shares	Sole	2025-02-14
No filing history on record for this holder in this stock.